These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 37155984)

  • 1. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
    Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R; Patel A; Dahm L; Han C; Medders KE; Mowers R; Byington CL; Koliwad SK; Butte AJ
    JAMA Netw Open; 2023 Oct; 6(10):e2336613. PubMed ID: 37782497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
    Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
    Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X; Zhang N; Lu L; Gao T; Chou OHI; Wong WT; Chang C; Wai AKC; Lip GYH; Zhang Q; Tse G; Liu T; Zhou J
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):103-117. PubMed ID: 37962962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor.
    Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
    Eur Heart J Qual Care Clin Outcomes; 2023 Jun; 9(4):397-407. PubMed ID: 35797996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
    J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
    ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK; Singh A; Singh R
    Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
    Htoo PT; Buse J; Cavender M; Wang T; Pate V; Edwards J; Stürmer T
    J Am Heart Assoc; 2022 Feb; 11(4):e022376. PubMed ID: 35132865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
    Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
    J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Tang H; Lu Y; Donahoo WT; Shao H; Shi L; Fonseca VA; Guo Y; Bian J; Guo J
    Ann Intern Med; 2024 Aug; 177(8):1004-1015. PubMed ID: 39008852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
    Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
    Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.
    Ko HY; Bea S; Jeong HE; Park S; Cho YM; Kong SH; Shin JY
    JAMA Netw Open; 2023 Sep; 6(9):e2335797. PubMed ID: 37751205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
    Chou OHI; Chauhan VK; Chung CTS; Lu L; Lee TTL; Ng ZMW; Wang KKW; Lee S; Liu H; Pang RTK; Kaewdech A; Cheung BMY; Tse G; Zhou J
    Gastric Cancer; 2024 Sep; 27(5):947-970. PubMed ID: 38856768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.